Lentigen has assembled a leading intellectual property portfolio in the field of lentiviral delivery technology.  This portfolio encompasses 15 patent families in the field of Lentiviral vectors and their use in a variety of applications in biotechnology and biomedicine. The Company has made a significant investment both in the development of its proprietary LV technology portfolio and in the consolidation of important third party intellectual property portfolios. In 2007, Greenwich Biotechnology Partners purchased for Lentigen the entire Cell Genesys Lentiviral vector estate, widely considered as the dominant intellectual property portfolio in the field.

The company also acquired Cambridge University Lentiviral vector technology, which broadly claims the use of HIV-based Lentiviral vectors.

Internally, the Company has developed strong patent coverage for its LV delivery system.  Its patent filings are focused on:

• Novel LV system compositions and methods
• Use of LV systems s for Influenza VLP manufacturing
• Use of Novel LV systems for protein manufacturing

The company has also in-licensed several key payload technologies for the treatment of specific diseases:

TMPK technology allows for safely deleting cells from the body in combination with AZT. This technology has wide utility in a variety of biomedical applications. It can be used to control cell fate in stem cell research, by specifically deleting unwanted cell types. It can be used in cell therapy as a "safety switch" to delete cells after they have had their therapeutic effect.

MGMT technology allows for selection of blood cells in the body after transduction of hematopoietic stem cells. Such technology can be used to select for blood cells that additionally express genes or RNAi to inhibit tumor formation, or for example, in the treatment of Leukemias with translocation abnormalities or various blood-borne pathogens such as HIV-AIDS.

Lentigen continues to in-license technologies that add value to its current Lentiviral vector portfolio.